MaxCyte publishes corporate presentation on scalable electroporation platform for cell and gene therapies

Reuters2026/08/12 20:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MaxCyte outlined its cell-engineering platform strategy focused on non-viral electroporation for ex vivo cell and gene therapy manufacturing.
2025 revenue of USD 33 million; non-GAAP adjusted gross margin of 81%.
Cash and cash equivalents of USD 142 million as of June 30, 2026.
Strategic platform license portfolio: 29 SPL customers; 13 clinical and commercial therapies supported; CASGEVY listed as a commercial program.
Clinical SPL pipeline: 12 active clinical programs; about USD 110 million in precommercial milestone potential; more than USD 30 million milestones received to date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MaxCyte Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MaxCyte publishes corporate presentation on scalable electroporation platform for cell and gene therapies

You may also like

Crypto prices